For example, losartan was found to suppress the development of liver fibrosis in rats by inhibiting the expression of the Toll-like receptor (TLR4) and nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NF-κB), as well as attenuating lipopolysaccharide-induced increase in myeloid differentiation factor 88, NF-κB, and TGF-β [107]. This evidence concerns the gene NFKB1 and Hepatic fibrosis.